Fund supports domestic commercial-scale vaccines and biotherapeutics manufacturing projects to improve health resilience for future pandemics.
The UK Biomanufacturing Fund (BMF) will provide up to £38 million in capital grants to incentivize investment in the manufacture of vaccines and biotherapeutics.
The BMF follows on from the £60 million Life Sciences Innovative Manufacturing Fund and the £20 million Medicines and Diagnostics Manufacturing Transformation Fund. The BMF will increase health resilience in the UK for future pandemics through increased domestic capacity, and more flexibility to re-deploy resources in an emergency.
Applications are currently being accepted for investment from companies manufacturing active pharmaceutical ingredient, component materials (starting materials, delivery systems, adjuvants), or conducting fill/finish of vaccines and biotherapeutics
Funding for this effort is focused on manufacture of human medicines, and will not be open to veterinary medicines or consumables (such as vials or syringes). Qualifying projects must be a manufacturing project (for commercial sale or clinical trials); be located in the UK; and have a total investment value of more than £12 million.
Applications for Phase 1 are due 30 June 2023.